Altimmune (NASDAQ:ALT) Now Covered by UBS Group

UBS Group assumed coverage on shares of Altimmune (NASDAQ:ALT) in a research note issued to investors on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $26.00 target price on the stock.

ALT has been the subject of a number of other research reports. Evercore ISI raised Altimmune to a “strong-buy” rating in a report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a report on Thursday, August 22nd. Finally, B. Riley restated a “buy” rating and set a $20.00 target price on shares of Altimmune in a research note on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Altimmune Price Performance

Shares of Altimmune stock opened at $7.61 on Tuesday. Altimmune has a 1 year low of $2.34 and a 1 year high of $14.84. The firm’s 50-day moving average is $7.02 and its 200 day moving average is $6.91. The stock has a market cap of $541.22 million, a price-to-earnings ratio of -4.91 and a beta of 0.09.

Altimmune (NASDAQ:ALT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. The firm had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the prior year, the company posted ($0.39) EPS. On average, equities analysts expect that Altimmune will post -0.54 EPS for the current fiscal year.

Insider Activity at Altimmune

In other Altimmune news, Director David Drutz sold 16,011 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $6.90, for a total value of $110,475.90. Following the completion of the sale, the director now owns 41,958 shares in the company, valued at $289,510.20. This represents a 27.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Altimmune

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Larson Financial Group LLC bought a new position in shares of Altimmune during the third quarter worth $31,000. CANADA LIFE ASSURANCE Co bought a new position in shares of Altimmune during the 1st quarter valued at about $44,000. TFO Wealth Partners LLC purchased a new position in shares of Altimmune during the first quarter valued at about $51,000. Horizon Wealth Management LLC bought a new stake in shares of Altimmune in the second quarter worth about $66,000. Finally, PFG Investments LLC purchased a new stake in shares of Altimmune in the second quarter worth about $67,000. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.